Expertise in
35
conditions

Dr. Daniel T. Layish

Pulmonary Medicine | Intensive Care Medicine
1115 E Ridgewood St, 
Orlando, FL 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
35
conditions
1115 E Ridgewood St, 
Orlando, FL 

Overview

Daniel Layish is a Pulmonary Medicine specialist and an Intensive Care Medicine provider practicing medicine in Orlando, Florida.

Dr. Layish is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Cystic Fibrosis, Lung Metastases, Secondary Immunodeficiency (SID), Chronic Obstructive Pulmonary Disease (COPD), and Gastrostomy.

Dr. Layish is board certified in American Board Of Internal Medicine - CCM, American Board Of Internal Medicine, and American Board Of Internal Medicine-Pulmonary Dis. He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 7 clinical trials. Dr. Layish is currently accepting new patients.

Specialties

Pulmonary Medicine
Intensive Care Medicine

Licenses

Internal Medicine in FL

Board Certifications

American Board Of Internal Medicine - CCM
American Board Of Internal Medicine
American Board Of Internal Medicine-Pulmonary Dis

Fellowships

Duke University Medical Center - GME: Orthopaedic Surgery

Hospital Affiliations

Adventhealth Orlando
Orlando Health
Adventhealth Waterman

Languages Spoken

English
Hebrew
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 24 Less Insurance Carriers -

Locations

Central Florida Pulmonary Group, PA
1115 E Ridgewood St, Orlando, FL 32803

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Completed
Publish Date: June 16, 2026
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
Enrollment Status: Completed
Publish Date: January 18, 2023
Intervention Type: Drug, Other
Study Drug: Lenabasum
Study Phase: Phase 2
An Open-label, Non-controlled, Multicenter, Pilot Trial, Using Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial (NTM) Infection
An Open-label, Non-controlled, Multicenter, Pilot Trial, Using Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial (NTM) Infection
Enrollment Status: Terminated
Publish Date: January 10, 2023
Intervention Type: Device, Drug
Study Phase: Phase 2
A Phase III, Randomized, Double-blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients
A Phase III, Randomized, Double-blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients
Enrollment Status: Completed
Publish Date: December 16, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects
Enrollment Status: Terminated
Publish Date: February 02, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Investigating the Optimal Dose Regimen, Efficacy, and Safety of Adding Oral Cysteamine in Adult Patients Being Treated for an Exacerbation of CF-associated Lung Disease
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Investigating the Optimal Dose Regimen, Efficacy, and Safety of Adding Oral Cysteamine in Adult Patients Being Treated for an Exacerbation of CF-associated Lung Disease
Enrollment Status: Completed
Publish Date: April 14, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients With Cystic Fibrosis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients With Cystic Fibrosis
Enrollment Status: Completed
Publish Date: September 04, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

1 Total Publications

Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial.
Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial.
Journal: PloS one
Published: July 10, 2020
Similar Doctors
Expertise in
14
conditions
Dr. Debabrata S. Bandyopadhyay
Intensive Care Medicine | Pulmonary Medicine
Expertise in
14
conditions
Dr. Debabrata S. Bandyopadhyay
Intensive Care Medicine | Pulmonary Medicine
Referral may be required

Florida Hospital Medical Group Inc

2600 Westhall Ln, 
Maitland, FL 
 (6.5 miles away)
407-200-2700
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Debabrata Bandyopadhyay is an Intensive Care Medicine specialist and a Pulmonary Medicine provider practicing medicine in Maitland, Florida. Dr. Bandyopadhyay is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Acute Interstitial Pneumonia, Interstitial Lung Disease, Sarcoidosis, Bone Graft, and Lung Transplant. Dr. Bandyopadhyay is currently accepting new patients.

Expertise in
22
conditions
Dr. Fortune O. Alabi
Pulmonary Medicine | Intensive Care Medicine
Expertise in
22
conditions
Dr. Fortune O. Alabi
Pulmonary Medicine | Intensive Care Medicine
Referral may be required

Florida Lung Asthma And Sleep Specialists, P.A.

3480 Polynesian Isle Boulevard, 
Kissimmee, FL 
 (15.8 miles away)
407-507-2615
Languages Spoken:
English, Urdu, Yoruba
See accepted insurances
Accepting New Patients
Offers Telehealth

Fortune Alabi is a Pulmonary Medicine specialist and an Intensive Care Medicine provider practicing medicine in Kissimmee, Florida. Dr. Alabi is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Asthma, Lung Metastases, Asthma in Children, and Pleural Effusion. Dr. Alabi is board certified in American Board Of Internal Medicine-Sleep Medicine, American Board Of Internal Medicine, and American Board Of Internal Medicine-Pulmonary Dis. Dr. Alabi is currently accepting new patients.

Expertise in
31
conditions
Dr. Ahmad S. Jalloul
Pulmonary Medicine | Intensive Care Medicine
Expertise in
31
conditions
Dr. Ahmad S. Jalloul
Pulmonary Medicine | Intensive Care Medicine
Referral may be required

Pulmonary Critical Care & Sleep Specialists Of Lake County PA

3121 Citrus Tower Blvd, 
Clermont, FL 
 (22.1 miles away)
352-404-5968
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Ahmad Jalloul is a Pulmonary Medicine specialist and an Intensive Care Medicine provider practicing medicine in Clermont, Florida. Dr. Jalloul is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Lung Nodules, Asthma in Children, and Advanced Bronchoscopy. Dr. Jalloul is board certified in American Board Of Internal Medicine. Dr. Jalloul is currently accepting new patients.

Frequently Asked Questions about Dr. Daniel T. Layish

How do I make an appointment with Dr. Daniel T. Layish?

You can book an appointment with Dr. Daniel T. Layish by calling their office at 407-841-1100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Daniel T. Layish a top-rated expert for Cystic Fibrosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Daniel T. Layish is classified as an Distinguished expert for Cystic Fibrosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Daniel T. Layish specialize in?

While Dr. Daniel T. Layish is a Pulmonary Medicine, they have specific expertise in Cystic Fibrosis, Lung Metastases, and Secondary Immunodeficiency (SID). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pulmonary Medicine.

Does Dr. Daniel T. Layish participate in research or clinical trials?

Yes. Dr. Daniel T. Layish has published 1 articles and abstracts on conditions like Cystic Fibrosis. You can view a list of Dr. Daniel T. Layish's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Daniel T. Layish accept my insurance?

Dr. Daniel T. Layish accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 407-841-1100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Layish's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 28 Advanced Conditions
    View All 25 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile